Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2023-11-01
2026-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery
NCT00104936
Proton/Photon Rt - Benign Meningiomas(P92-13)
NCT02947984
Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.
NCT05081908
Proton Radiation For Meningiomas and Hemangiopericytomas
NCT01117844
Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND
NCT07282470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will explore the dynamic of plasma EVs in meningioma patients under/after radiotherapy, with the objective of identifying potential biomarkers of (early) tumor progression. DNA methylation profiling of plasma EVs in meningioma patients may enable molecular risk stratification, facilitating a molecularly-guided clinical management in meningioma patients in the future.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Explorative biomarker study
Analysis of blood biomarker
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse)
* indication for radiotherapy
* completed wound healing after surgical intervention)
* Alter ≥ 18 Jahre
* Karnofsky Performance Score ≥ 60%
* written informed consent
* ability of subject to understand character and individual consequences of the trial
* adequate contraception for women of childbearing potential
Exclusion Criteria
* previous (cerebral) radiotherapy
* simultaneous chemo/immunotherapy
* evidence that the patient cannot adhere to the study protocol (e.g., non-compliance)
* the refusal of patients to participate in the study
* participation in another clinical study or observation period in a competing trial
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Heidelberg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juergen Debus
Department head
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RADONK-MOLI-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.